DGTR Opens Seven Anti-Dumping Probes on Chinese Imports — Pharma APIs, Rubber Resin, Elevator Rails and Polyol

What happened: India's Directorate General of Trade Remedies (DGTR) has initiated seven separate anti-dumping investigations into imports from China, through notifications issued between 23 and 28 September 2026. Six of the probes target China alone; the investigation into 6-Amino Penicillanic Acid (6-APA) also covers the European Union. The products span pharmaceutical ingredients, a rubber/tyre chemical, elevator components and a foam input. Importers who source these goods from China (or the EU, for 6-APA) should prepare for the possibility of provisional and later definitive anti-dumping duties.

What Happened

According to trade reports, DGTR initiated probes on the following seven products, each on an application from a domestic producer:

• Penicillin G and its salts (antibiotic starting material) — applicant Lyfius Pharma.
• 6-Amino Penicillanic Acid (6-APA) (beta-lactam antibiotic intermediate) — applicant Qule Pharma; China and the EU.
• Amoxycillin Trihydrate (API) — applicant Apitoria Pharma (Aurobindo group).
• Montelukast Sodium (respiratory/allergy API) — applicant Morepen Laboratories.
• Para-tert-Octyl Phenol (PTOP) Formaldehyde Tackifier Resin (tyre/rubber manufacturing) — applicants SI Group India and Finorchem.
• T-shaped elevator/lift solid guide rails — applicant Saver India Riding Systems.
• Copolymer Polyol (flexible foam for mattresses and auto components) — applicant Expanded Polymer Systems.

An anti-dumping initiation is the start of an inquiry, not a duty. DGTR will examine whether the goods are being exported to India below normal value and whether that injures the domestic industry, before recommending any provisional or definitive duty.

Why / Background

Several of these products are concentrated in Chinese supply — notably antibiotic APIs and intermediates, where India's formulators depend heavily on imported fermentation-based inputs. Domestic producers argue that low-priced imports undercut their investments in local API capacity, a concern aligned with the government's broader push for pharmaceutical self-reliance. The clustering of multiple pharma-API probes in a single week underscores that emphasis.

Who's Affected

Importers and formulators sourcing Penicillin G, 6-APA, Amoxycillin Trihydrate or Montelukast Sodium from China (and 6-APA from the EU) are most exposed, because antibiotic supply chains are price-sensitive and import-dependent. Tyre and rubber manufacturers using PTOP tackifier resin, elevator and lift companies importing guide rails, and foam/mattress and auto-component makers using copolymer polyol are also affected. Chinese (and, for 6-APA, EU) exporters named in the probes can participate in the investigation by filing questionnaire responses.

Key Operational Details

• Trigger: seven separate DGTR notifications dated between 23 and 28 September 2026.
• Scope: six China-only; 6-APA covers China and the EU.
• Stage: investigation initiated; no duty applies yet. Provisional duty (if any) would follow a preliminary finding.
• Participation: interested parties (importers, exporters, users) can register and file submissions within DGTR's timelines.

What Importers Should Do Now

• Map your exposure. Identify which of the seven products you import, the volumes, and your reliance on Chinese (or EU, for 6-APA) sources.
• Register as an interested party with DGTR if duties would materially affect you, and file importer/user submissions within the deadline.
• Build duty scenarios into procurement: model landed cost if a provisional duty is imposed, and identify alternative or domestic sources.
• Lock near-term contracts carefully — provisional duties can take effect on short notice once a preliminary finding is issued.

What Exporters, Forwarders and CHAs Should Do Now

• Forwarders/CHAs: flag these tariff lines for importer clients so they are not surprised by a future provisional-duty notification at assessment.
• Downstream exporters (e.g., formulators who export finished antibiotics) should assess how a duty on inputs could affect their own cost competitiveness.

The Bigger Picture

This batch of probes continues a steady run of Indian trade-remedy action on Chinese imports, with a clear tilt toward pharmaceutical APIs and intermediates. For import-dependent sectors, the message is to treat China-sourced inputs in these categories as carrying regulatory risk over the coming months and to diversify where feasible. Whether duties ultimately follow depends on DGTR's findings on dumping and injury.

Frequently Asked Questions

Q: Do I have to pay anti-dumping duty now? A: No. These are investigations. Duties, if any, come only after DGTR's findings — provisional first, then definitive.

Q: Which probe affects EU suppliers? A: The 6-Amino Penicillanic Acid (6-APA) investigation covers both China and the European Union. The other six target China.

Q: Can importers and users have a say? A: Yes. Importers and user industries can register as interested parties and file submissions within DGTR's timelines.

Q: How long do these investigations take? A: Anti-dumping inquiries typically run several months to a year, with provisional measures possible earlier if a preliminary finding warrants them.

Conclusion

Seven fresh DGTR probes put Chinese imports of key antibiotic APIs, a rubber resin, elevator rails and foam polyol under the anti-dumping microscope. No duty applies yet, but importers in these categories should map exposure, engage with DGTR, and plan for a possible duty.

This summary is for general guidance only. Verify product scope, dates and status against the official DGTR notifications at dgtr.gov.in before acting.